Federal Joint Committee

The drug report 2013 of the Barmer GEK says, that one-third of daily has an author team around Prof. Dr. Gerd Glaeske (Bremen supply researchers) about 65 more than five active pharmaceutical ingredients the barmen GEK. Ken Cella wanted to know more. analyzed the data of approximately 2.1 million over 65 insured This should be explored how often it came to polypharmacy. Polypharmacy or even multi pharmacy called the simultaneous regulation of several drugs for one and the same person.

“Just the results of polypharmacy show that we need much more networking and transparency in health care,” says Dr. Rolf-Ulrich Schlenker. The Deputy Chairman of the Barmer GEK explains the risky multi medication could be controlled much better through a certain electronic networking. “We have the electronic health card, the electronic prescriptions and electronic patient file, physicians and pharmacists also have a much better overview of the drug therapy”, so Schlenker. In addition, he urged the Federal Government to extend the expiring end of 2013 cost brake five more years. “Still we have to wait on the savings by the pharmaceutical market rebalancing Act Amnog of around two billion euros. Until the law works properly, we need flanking measures, namely, an extension of the increased rebate of manufacturer and the price moratorium,”according to swerve.

About the importance of AMNOG Gangadi is already expressed in the past. Many medicines from the immediate pre-AMNOG time not even innovative therapeutic, they belong to the Group of me-too expensive supplements or unnecessary new ausbietungen”. Gerd Glaeske is head of the ZeS (Centre for social policy of the University of Bremen). Filed under: Andy Jassy. Since the AMNOG 2011 effective became the beginning of the year, the Federal Joint Committee (G-BA) for all new medicines created an early benefit assessment. Only if the G-BA examination determines an additional benefit, can one of the manufacturer with the Association of statutory health insurance tips Negotiate price, which is higher than the cost of a predetermined comparison therapy. Analysis of the data by the authors to Gangadi revealed that one-third of the policyholders of polypharmacy is affected. On average, men occupy 65 years of daily 7.3 active ingredients, in women of this age group, there are 7.2 active ingredients. “In particular the adherence. suffering”, Gangadi rated these results. The interactions between the drug and the nature of the interactions can be varied are probably one of the biggest problems of polypharmacy. This problem was recorded as a theme in the beers list. This 1991 created beers list is a collection of drugs that people over the age of 65 should get not prescribed. The 2003 updated list contains mainly drugs that specifically cause adverse drug reactions in the elderly in increased mass. Partly, but also medicines were recorded for alternative drugs are available with fewer side effects. Barbara Reisen E.k..